Saad Z. Usmani, MD, MBA, FACP, on Response Rates From CARTITUDE-1 Trial at 2021 ASCO


Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, spoke with CancerNetwork® at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, about the overall response and complete response rates of patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) from the CARTITUDE-1 trial.


At the 12.4-month follow-up at [the American Society for Hematology Annual Meeting], the overall response rate was 97% and the stringent [complete response (CR)] rate was 67%. At that time, because of the follow up period, the 12-month [progression-free survival (PFS)], and overall survival (OS)] rates were reported at 77% and 89%. With this further follow-up, what we’re finding is an overall response rate of 98%. The response rate has improved because we have another evaluable patient and the responses have deepened, so a stringent CR rate of 80.4% was observed. The median time to best response and median time to CR or better were 2.6 months. The median duration of response for the whole population—again, because of not having enough follow-up, you have to take this with a grain of salt—the median duration of response is 21.8 months and I suspect that with subsequent follow-up, that may actually improve because most of the patients are [in] stringent CR, and the duration of response in those patients hasn’t been reached.

The 18-month PFS and OS rates are 66% and 81%. With the follow-up, the PFS and OS continue to be quite impressive. We did not see any new safety signals. As we know with CAR T-cell therapy, most of the [adverse] effects tend to happen earlier in the course and since patients are not on any ongoing treatment, their quality of life continues to improve and that’s what we saw here.


Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021,39(suppl 15; abstr 8005). doi:10.1200/JCO.2021.39.15_suppl.8005

Related Videos
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content